Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Catalyst Pharmaceuticals Inc    CPRX

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/05/2016 12/06/2016 12/07/2016 12/08/2016 12/09/2016 Date
1.15(c) 1.15(c) 1.12(c) 1.15(c) 1.18(c) Last
741 036 248 514 530 656 543 163 367 065 Volume
+4.55% 0.00% -2.61% +2.68% +2.61% Change
More quotes
Financials ($)
Sales 2016 -
EBIT 2016 -20,6 M
Net income 2016 -19,8 M
Debt 2016 -
Yield 2016 -
Sales 2017 -
EBIT 2017 -24,6 M
Net income 2017 -24,5 M
Debt 2017 -
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales2016 0
Capi. / Sales2017 0
Capitalization 97,8 M
More Financials
Company
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company.It focuses on development and commercialization of prescription drugs targeting rare (orphan) neuromuscular and neurological diseases, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and Tourette's disorder.The... 
More about the company
Surperformance© ratings of Catalyst Pharmaceuticals I
Trading Rating : Investor Rating : -
More Ratings
Latest news on CATALYST PHARMACEUTICALS I
12/08 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
12/08 Catalyst Pharmaceuticals Provides Update on its Clinical Trial for Patients w..
11/21 CATALYST PHARMACEUTICALS : to Participate in the 28th Annual Piper Jaffray Healt..
11/10 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Announces Third Quarte..
11/09 CATALYST PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits..
11/09 Catalyst Pharmaceuticals Announces Third Quarter 2016 Financial Results and P..
11/09 CATALYST PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CON..
11/01 Catalyst Pharmaceuticals to Hold Third Quarter Financial Results Conference C..
10/31 CATALYST PHARMACEUTICALS, INC. (CPRX : FDA OKs Phase 3 Firdapse Study; Shares Hi..
10/31 CATALYST PHARMACEUTICALS, INC. (NASD : CPRX) Files An 8-K Receives Special Proto..
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11/10 Catalyst Pharmaceutical Partners' (CPRX) CEO Patrick McEnany on Q3 2016 Resul..
11/09 Catalyst Pharmaceutical beats by $0.01
10/31 FDA signs off on design of Catalyst Pharma's late-stage study of Firdapse in ..
10/07 Healthcare ratings roundup - Upgrades/Downgrades
10/05 Catalyst Pharma shows some oomph; shares up 29%
Advertisement
Chart CATALYST PHARMACEUTICALS I
Duration : Period :
Catalyst Pharmaceuticals I Technical Analysis Chart | CPRX | US14888U1016 | 4-Traders
Full-screen chart
Technical analysis trends CATALYST PHARMACE...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 4,38 $
Spread / Average Target 271%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Patrick J. McEnany Chairman, President, CEO & Contact Person
Steven R. Miller Chief Operating & Scientific Officer
Alicia Grande Chief Financial Officer, Treasurer & VP
Gary Ingenito Chief Medical Officer
Philip H. Coelho Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CATALYST PHARMACEUTICA..-51.84%98
AMGEN, INC.-11.63%106 716
GILEAD SCIENCES, INC.-28.16%95 779
CELGENE CORPORATION-5.25%87 962
REGENERON PHARMACEUTIC..-31.32%39 322
ACTELION LTD50.21%22 204
More Results